Inversago’s lead asset, INV-202, specifically blocks the receptor protein CB1, which plays key role in metabolism and appetite regulation in peripheral tissues such as adipose tissues, the GI tract, kidneys, liver, pancreas, muscles and lungs
Novo Nordisk finished products assembly unit. (Credit: Novo Nordisk A/S)
Danish pharmaceutical company Novo Nordisk has agreed to acquire Canada-based Inversago Pharma for up to $1.07bn in cash, including development and commercial milestone payments.
Established in 2015, Inversago is engaged in developing CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
The acquisition includes Inversago’s lead asset INV-202, an oral CB1 inverse agonist that specifically blocks the receptor protein CB1.
The CB1 protein is believed to play key role in metabolism and appetite regulation in peripheral tissues such as adipose tissues, the GI tract, kidneys, liver, pancreas, muscles and lungs.
The acquisition is expected to be completed before the end of this year, subject to receipt of applicable regulatory approvals and other customary conditions.
Novo Nordisk development executive vice president Martin Holst Lange said: “The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders.
“This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity.”
Currently in a Phase 2 clinical trial for diabetic kidney disease (DKD), INV-202 has showed potential for weight loss, in a Phase 1b clinical trial.
Inversago is also developing additional assets for metabolic and fibrotic disorders.
Novo Nordisk plans to evaluate INV-202 for obesity and obesity-related complications.
According to studies across cardiometabolic and fibrotic diseases, the peripheral CB1 receptor blocking will address unmet needs for several people.
Inversago aims to focus on the completion of the ongoing and planned clinical trials and work closely with Novo Nordisk for future clinical trials.
Inversago Pharma chief executive officer François Ravenelle said: “We are delighted to join forces with a global leader in the obesity and metabolic disorder space.
“We believe this combination will help unlock the full medical potential of our CB1 blockers and may one day expand treatment options for people living with metabolic syndrome, obesity and related complications.
“Novo Nordisk has world-class research facilities, significant global reach and a rich culture of collaboration seeking to bring our therapeutic treatments to market.”